Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Neuronity
AddedFeb 18, 2024
UpdatedJun 18, 2026
Neuronity

Neuronity

Pre-Seed

Neuronity: A Massachusetts-based medical organization curing neurological disorders since 2022.

HQ
Mansfield, MA, US
Founded
2022
Overview
Compare
Fundraising
Employees
Website

Neuronity, founded in 2022 and headquartered in Mansfield, Massachusetts, is a medical organization dedicated to curing neurological disorders by enhancing the immunity of the central nervous system. The company focuses on developing innovative therapies that boost healthy immune cells in the aged nervous system, aiming to prevent the progression of neurodegenerative diseases. Neuronity's core mission is to address the decline in immune activity within the brain due to aging, thereby mitigating the onset of degenerative conditions.

Key figures associated with Neuronity include a team of specialized scientists committed to advancing neuroimmunity research. The company has made significant strides in understanding how immune activity impacts brain health and has developed promising therapeutic approaches. Neuronity's impact lies in its potential to revolutionize treatments for neurological disorders, offering hope for improved quality of life for aging populations worldwide.

Neuronity - Similar Companies

Neuron23 logo

Neuron23

NeuroTherapia logo

NeuroTherapia

neurotherapia.com

NeuroCytonix logo

NeuroCytonix

neurocytonix.com

Neurona Therapeutics logo

Neurona Therapeutics

Neuronascent logo

Neuronascent

neuronascent.com

Neuraly logo

Neuraly

neuralymed.com

Ryne Biotechnology logo

Ryne Biotechnology

Neuro42 logo

Neuro42

Neuro3 Therapeutics logo

Neuro3 Therapeutics

NeurOp logo

NeurOp

Neurana Pharmaceuticals logo

Neurana Pharmaceuticals

neuranapharma.com

Neuropure logo

Neuropure

Rejuvitas logo

Rejuvitas

rejuvitas.com

Reservoir Neuroscience logo

Reservoir Neuroscience

reservoirneuro.com

Neurolixis logo

Neurolixis

neurolixis.com

Neuronity - Quick Facts

Who are Neuronity's competitors?

Companies similar to Neuronity include Neuron23, NeuroTherapia, NeuroCytonix and Neurona Therapeutics.

When was Neuronity founded?

Neuronity was founded in 2022.

Where is Neuronity's headquarters located?

Neuronity's headquarters is located in Mansfield, MA, US.

When was Neuronity's last funding round?

Neuronity's most recent funding round was for $780k (USD) in July 2023.

How much has Neuronity raised to-date?

As of Jul 3, 2023, Neuronity has raised a total of $780k (USD).

How many employees does Neuronity have?

Neuronity has 5 employees as of Feb 4, 2024.

Neuronity - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • United States
Customer
  • Enterprise
Main Product
  • Medical Research
Tags
  • Biotech
  • Consulting
  • Healthtech
NAICS
  • 621000Ambulatory Health Care Services
  • 621300Offices of Other Health Practitioners
  • 621330Offices of Mental Health Practitioners (except Physicians)
  • 620000Health Care and Social Assistance
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified